Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Equity Bottom-Up

<ul><li>Veldona study design under review by TFDA. Ainos plans to initiate a Veldona clinical study in Taiwan for oral warts in HIV+ patients on antiretroviral therapy (ART), with trial start and first patient visit expected in November 2024.</li><li>The single-site, double-blind study will enroll 40 subjects, randomized 3:1 to Veldona or placebo.</li><li>The primary endpoint is the proportion of patients achieving &gt;75% reduction in oral warts surface area at 24 weeks, with secondary endpoints of &gt;50% reduction and patient- and physician-assessed quality of oral health. </li></ul>

Veldona study design under review by TFDA. Ainos plans to initiate a Veldona clinical study in Taiwan for oral warts in HIV+ patients on antiretroviral therapy (ART), with trial start and first patient visit expected in November 2024.The single-site, double-blind study will enroll 40 subjects, randomized 3:1 to Veldona or placebo.The primary endpoint is the proportion of patients achieving &gt;75% reduction in oral warts surface area at 24 weeks, with secondary endpoints of &gt;50% reduction and patient- and physician-assessed quality of oral health. 

Ainos, Inc. -  Veldona Oral Warts Trial to Start in Taiwan Before Year-End

<ul><li>Veldona patent granted in Taiwan for treatment and prevention of coronavirus infection, securing 20 years of patent protection.</li><li>The invention patent covers the method and composition of a Veldona-based therapeutic approach to stimulate the immune system by dosing Veldona through sublingual and/or buccal administration to reduce the risk of symptomatic coronavirus infections.</li><li>Sublingual and/or buccal administration allows Veldona to be rapidly absorbed by the oral mucosa, enabling more effective treatment and better drug compliance. </li></ul>

Veldona patent granted in Taiwan for treatment and prevention of coronavirus infection, securing 20 years of patent protection.The invention patent covers the method and composition of a Veldona-based therapeutic approach to stimulate the immune system by dosing Veldona through sublingual and/or buccal administration to reduce the risk of symptomatic coronavirus infections.Sublingual and/or buccal administration allows Veldona to be rapidly absorbed by the oral mucosa, enabling more effective treatment and better drug compliance. 

Ainos, Inc. - Adding Coronavirus Treatment and Prevention to Veldona Patent Portfolio

<ul>
<li>Advancing AI Nose beyond healthcare into smart manufacturing.</li>
<li>Ainos announced initial results from a VOC sensing program in industrial safety and smart manufacturing with its Japanese co-development partners.</li>
<li>As of August 15, 2024, AI Nose achieved 79% accuracy in detecting 22 different VOCs to identify 761 samples of potentially hazardous gases or contaminants. </li>
</ul>


Advancing AI Nose beyond healthcare into smart manufacturing.
Ainos announced initial results from a VOC sensing program in industrial safety and smart manufacturing with its Japanese co-development partners.
As of August 15, 2024, AI Nose achieved 79% accuracy in detecting 22 different VOCs to identify 761 samples of potentially hazardous gases or contaminants. 


Ainos, Inc.( AIMD): AI Nose Expanding into Industrial Smart Manufacturing

<ul><li>Ainos acquired exclusive, permanent licenses for 10 patents and patent applications from its affiliate and development partner, Taiwan Carbon Nano Technology (TCNT), for certain gas sensor and medical device technologies.</li><li>TCNT is also currently the sole manufacturer of Ainos’ POCTs. The patent coverage includes the US, Germany, China, Japan, and Taiwan.</li><li>The licensed IP will further enhance the company’s AI Nose and POCT platform, as the lead POCT product Ainos Flora progresses in clinical trial, and design completion for next-gen Ainos Flora with Nvidia CUDA is expected in 3Q24, with clinical <span style="font-size: var(--content-font-size);">trial starting in 4Q24. </span></li></ul>

Ainos acquired exclusive, permanent licenses for 10 patents and patent applications from its affiliate and development partner, Taiwan Carbon Nano Technology (TCNT), for certain gas sensor and medical device technologies.TCNT is also currently the sole manufacturer of Ainos’ POCTs. The patent coverage includes the US, Germany, China, Japan, and Taiwan.The licensed IP will further enhance the company’s AI Nose and POCT platform, as the lead POCT product Ainos Flora progresses in clinical trial, and design completion for next-gen Ainos Flora with Nvidia CUDA is expected in 3Q24, with clinical trial starting in 4Q24. 

Ainos, Inc. - AI Nose Patents Licensed from Key Partner with Shares Valued at a Premium

<ul><li>Ainos reported 2Q24 earnings, highlighting the pipeline progress in the quarter, including enrollment of the first subject in the Veldona animal clinical study for feline chronic gingivostomatitis (FCGS) and advancement of next-generation Ainos Flora with Nvidia CUDA implementation.</li><li>Financials. 2Q24 revenue was $0, as Ainos has pivoted away from COVID-19 antigen tests and focuses on AI Nose for the POCT platform and Veldona drugs.</li><li>Pet supplement product revenue in the quarter was deferred in contract liabilities. </li></ul>

Ainos reported 2Q24 earnings, highlighting the pipeline progress in the quarter, including enrollment of the first subject in the Veldona animal clinical study for feline chronic gingivostomatitis (FCGS) and advancement of next-generation Ainos Flora with Nvidia CUDA implementation.Financials. 2Q24 revenue was $0, as Ainos has pivoted away from COVID-19 antigen tests and focuses on AI Nose for the POCT platform and Veldona drugs.Pet supplement product revenue in the quarter was deferred in contract liabilities. 

United States

Ainos, Inc. is a diversified healthcare company. The Company engages in the discovery and development of novel biopharmaceuticals, technologically medical treatments, and consumer products, as well as provides treatments of neoplastic, viral, and autoimmune diseases. Ainos operates in the United States and Taiwan.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ainos (AIMD US)

Ainos, Inc. - Veldona Oral Warts Trial to Start in Taiwan Before Year-End

Veldona study design under review by TFDA. Ainos plans to initiate a Veldona clinical study in Taiwan for oral warts in HIV+ patients on...

Water Tower Research

Ainos, Inc. - Adding Coronavirus Treatment and Prevention to Veldona Patent Portfolio

Veldona patent granted in Taiwan for treatment and prevention of coronavirus infection, securing 20 years of patent protection.

Water Tower Research

Ainos, Inc.( AIMD): AI Nose Expanding into Industrial Smart Manufacturing

The results support AI Nose’s potential application in industrial automation and improving manufacturing safety monitoring.

Water Tower Research

Ainos, Inc. - AI Nose Patents Licensed from Key Partner with Shares Valued at a Premium

Ainos is also exploring to deploy VOC sensing to enable a safer work environment and better production quality in high-tech factories.

Water Tower Research

Ainos, Inc. - Earnings Update

Ainos reported 2Q24 earnings, highlighting the pipeline progress in the quarter, including enrollment of the first subject in the Veldona animal...

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)